LGNZZ
LIGAND PHARMACEUTICALS INC
Overview
Ligand Pharmaceuticals operates as a biopharmaceutical royalty company that acquires and structures royalty interests in mid- to late-stage development and commercial drug products, generating long-duration cash flows from partner-commercialized medicines.
LIGAND PHARMACEUTICALS INC has a $10.9M market cap.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
History
Earnings history
Reported quarters with consensus, surprise, and 1-day reaction context.
Track Record
SampleSpoken Alpha tracks LGNZZ's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.65 | $3.85 | +20.7% | +1.5% | -0.7% |
| Q4 FY2026 | $4.41 | $3.95 | +11.6% | -0.6% | -3.5% |
| Q3 FY2026 | $4.59 | $4.04 | +13.6% | +9.0% | +6.2% |
| Q2 FY2026 | $4.92 | $4.12 | +19.5% | +0.8% | +2.4% |
| Q1 FY2025 | $4.80 | $3.98 | +20.6% | +0.9% | -1.5% |
| Q4 FY2025 | $4.65 | $3.94 | +17.9% | -0.9% | -0.3% |
| Q3 FY2025 | $4.88 | $4.01 | +21.7% | +8.5% | +8.4% |
| Q2 FY2025 | $4.74 | $4.25 | +11.5% | -2.4% | -2.9% |
| Q1 FY2024 | $4.94 | $4.22 | +17.0% | -1.3% | -0.7% |
| Q4 FY2024 | $4.97 | $4.16 | +19.5% | +6.7% | +5.6% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Todd C DavisCEO6 mo14 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
- Octavio EspinozaCFO6 mo6 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • guidance suspended Q1 FY2026
- Andrew ReardonCLO & Secretary1 yrno recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • guidance suspended Q1 FY2026
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LGNZZ.
$ curl https://api.spokenalpha.com/v1/companies/LGNZZFAQ
Frequently asked about LGNZZ
Where can I find LIGAND PHARMACEUTICALS INC's (LGNZZ) earnings call transcripts?
Spoken Alpha indexes LGNZZ's earnings call transcripts at https://spokenalpha.com/companies/LGNZZ. Each call links to attributed speakers and parsed analyst Q&A. LIGAND PHARMACEUTICALS INC's own investor relations page is at https://investor.ligand.com/overview/default.aspx.